Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/180608
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered 'undruggable', several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.
Matèries
Matèries (anglès)
Citació
Citació
LINDSAY, Colin r., GARASSINO, Marina c., NADAL, Ernest, ÖHRLING, Katarina, SCHEFFLER, Matthias, MAZIÈRES, Julien. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. _Lung Cancer_. 2021. Vol. 160, núm. 152-165. [consulta: 21 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/180608]